<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00753571</url>
  </required_header>
  <id_info>
    <org_study_id>PUTH-1</org_study_id>
    <nct_id>NCT00753571</nct_id>
  </id_info>
  <brief_title>Cistanche Total Glycosides for Amyotrophic Lateral Sclerosis: A Randomized Control Trial (RCT) Study Assessing Clinical Response</brief_title>
  <official_title>Cistanche Total Glycosides Treatment for Amyotrophic Lateral Sclerosis: A Randomized Control Trial Study Assessing Clinical Response</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating&#xD;
      patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease&#xD;
      that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and&#xD;
      motor cortex. Patients develop progressive wasting and weakness of both upper and lower&#xD;
      limbs, bulbar and respiratory muscles. Usually death from respiratory failure typically is&#xD;
      within 3-5 years of diagnosis. Although there are various treatments for ALS, riluzole is the&#xD;
      only approved treatment to delay the disease progression. Cistanche Total Glycosides is an&#xD;
      approved drug that has protective effects. It acts anti-apoptosis by activating several&#xD;
      protective pathways, stimulates neuronal differentiation of adult neural stem cells in the&#xD;
      brain, and improves long-term recovery. CTG is a highly attractive candidate for the&#xD;
      treatment of neurodegenerative conditions such as ALS.&#xD;
&#xD;
      Patients 18 to 65 years of age who have had mild to moderately severe ALS for 0.5 to 2 years&#xD;
      of duration may be eligible for this study. Candidates will be screened with a medical&#xD;
      history and possible review of medical records, physical examination, blood test, urine and&#xD;
      stool analyses, electrocardiogram, electrophysiological examination, neurological imaging&#xD;
      and, for women, a pregnancy test.&#xD;
&#xD;
      Participants will have drug therapy according to randomized number. One group receives CTG&#xD;
      while other group receives placebo. For the procedure, patients are given a medication to&#xD;
      lessen anxiety and any discomfort. Patients receive drugs for 9 months. The CTG dosage is&#xD;
      1.8g/day. Physical examination and interview, Appel ALS scale and ALS-Functional Rating Scale&#xD;
      will be done in 28 days and 3, 6, 9months. Electrophysiological examination will be tested&#xD;
      per 3 months. Blood samples will be collected on treat28 days and 3, 6, 9months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will examine the effectiveness of Cistanche Total Glycosides(CTG) in treating&#xD;
      patients with amyotrophic lateral sclerosis (ALS) - a fatal neurological degenerative disease&#xD;
      that causes adult-onset, progressive motor neurons loss in the spinal cord, brain stem and&#xD;
      motor cortex. Patients develop progressive wasting and weakness of both upper and lower&#xD;
      limbs, bulbar and respiratory muscles. Usually death from respiratory failure typically is&#xD;
      within 3-5 years of diagnosis. Although there are various treatments for ALS, riluzole is the&#xD;
      only approved treatment to delay the disease progression. Cistanche Total Glycosides is an&#xD;
      approved drug that has protective effects. It acts anti-apoptosis by activating several&#xD;
      protective pathways, stimulates neuronal differentiation of adult neural stem cells in the&#xD;
      brain, and improves long-term recovery. CTG is a highly attractive candidate for the&#xD;
      treatment of neurodegenerative conditions such as ALS.&#xD;
&#xD;
      Patients 18 to 65 years of age who have had mild to moderately severe ALS for 0.5 to 2 years&#xD;
      of duration may be eligible for this study. Candidates will be screened with a medical&#xD;
      history and possible review of medical records, physical examination, blood test, urine and&#xD;
      stool analyses, electrocardiogram, electrophysiological examination, neurological imaging&#xD;
      and, for women, a pregnancy test.&#xD;
&#xD;
      Participants will have drug therapy according to randomized number. One group receives CTG&#xD;
      while other group receives placebo. For the procedure, patients are given a medication to&#xD;
      lessen anxiety and any discomfort. Patients receive drugs for 9 months. The CTG dosage is&#xD;
      1.8g/day. Physical examination and interview, Appel ALS scale and ALS-Functional Rating Scale&#xD;
      will be done in 28 days and 3, 6, 9months. Electrophysiological examination will be tested&#xD;
      per 3 months. Blood samples will be collected on treat28 days and 3, 6, 9months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">October 2010</completion_date>
  <primary_completion_date type="Anticipated">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The mean rate of decline of ALS-FRS score</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The mean rate decline of the AARS score</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1,CTG,po</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cistanche Total Glycosides</intervention_name>
    <description>Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd*9months Arms: 1 Drug: blank capsules 6 capsules po Qd*9months&#xD;
Arms: 2</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All subjects must have a verifiable diagnosis of ALS of 0.5 to 2 years' duration.&#xD;
&#xD;
          -  The diagnosis must be supported by the Revised Criteria of the World Federation of&#xD;
             Neurology.&#xD;
&#xD;
          -  The grades of diagnosis must be clinically definite ALS or clinically probable ALS.&#xD;
&#xD;
          -  All subjects must be over age 18 and below 65.&#xD;
&#xD;
          -  The ALS is mildly to moderate based on ALS Health State Scale.&#xD;
&#xD;
          -  Electrophysiological features show CMAP amplitude of motor nerve normal or mild&#xD;
             declining.&#xD;
&#xD;
          -  Serum creatine kinase is normal or mild upper, less than 500U/L.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  If anyone of the above eligibility requirements is not met&#xD;
&#xD;
          -  Use of any other investigational agent within 30 days beginning the treatment phase of&#xD;
             this study&#xD;
&#xD;
          -  Severe cardiac, pulmonary, hepatic or/and hematic disease&#xD;
&#xD;
          -  HIV positivity or signs and symptoms consistent with HIV infection&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  History of cancer with less than 5 years documentation of a disease-free state&#xD;
&#xD;
          -  History of anaphylactic reaction or hypersensitivity to G-CSF or proteins derived from&#xD;
             E.coli&#xD;
&#xD;
          -  Alcohol or drug abuse in recent 1 year&#xD;
&#xD;
          -  Can't understand or obey the rules of treatment&#xD;
&#xD;
          -  Blood donor in recent 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dongsheng Fan MD Fan, Docter</last_name>
    <phone>+861082265250</phone>
    <phone_ext>0</phone_ext>
    <email>dsfan@sina.com ; chinaals@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wang Liping Wang</last_name>
    <phone>+861082265024</phone>
    <email>chinaals@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongsheng Fan, MD; Liping Wang,MD</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100191</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dongsheng Fan MD Fan, Docter</last_name>
      <phone>+861082265250</phone>
      <phone_ext>0</phone_ext>
      <email>chinaals@gmail.com;dsfan@sina.com ;</email>
    </contact>
    <contact_backup>
      <last_name>Liping Wang MD Wang, doctor</last_name>
      <phone>+8613810002694</phone>
      <email>chinaals@gmail.com;dianer@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.als.net/</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2008</verification_date>
  <study_first_submitted>September 15, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>December 29, 2009</last_update_submitted>
  <last_update_submitted_qc>December 29, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 30, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dongsheng Fan, MD</name_title>
    <organization>Peiking University Third Hospital</organization>
  </responsible_party>
  <keyword>Amyotrophic Lateral Sclerosis</keyword>
  <keyword>Cistanche Total Glycosides</keyword>
  <keyword>Randomized Control Trial Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiac Glycosides</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

